2nd Quarter - Report

AMERICAN SOCIETY FOR CLINICAL PATHOLOGY for AMERICAN SOCIETY FOR CLINICAL PATHOLOGY

Firm
Client
Income
—
Expenses
$46,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Stark Self-Referral Reform; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments ; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; federal oversight of laboratory tests including laboratory developed testing services; immigration

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Veterans Affairs, Dept of (VA); Homeland Security, Dept of (DHS); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); SENATE; Health & Human Services, Dept of (HHS)

Labor Issues/Antitrust/Workplace LBR

Physician, clinical laboratory professional, and allied health workforce issues, Federal Funding for Education, Student loan Repayment/Forgiveness, and Related Workforce Development; Workforce Reinvestment Act; Federal Healthcare Workforce Issues; Appropriations for Federal Agencies; Clinical Laboratory Improvement Amendments; COVID-19 Response and Laboratory Test Capacity; immigration issues impacting laboratory workforce

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Education, Dept of; Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Employment & Training Administration; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Bureau of Citizenship & Immigration Services (BCIS); Centers For Disease Control & Prevention (CDC); Homeland Security, Dept of (DHS)

Medicare/Medicaid MMM

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Centers For Disease Control & Prevention (CDC); Bureau of Labor Statistics (BLS); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.